Stock comparison
LeMaitre Vascular
Xeris Biopharma Holdings
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.32B
Sector
Healthcare
XERS
Xeris Biopharma Holdings
Market cap
$1.13B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | XERS | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 49D | LMAT |
| Benjamin Graham | 81A | 75B | LMAT |
| Philip Fisher | 73B | 64C | LMAT |
| Peter Lynch | 59C | 80A | XERS |
| Joel Greenblatt | 48D | 48D | Tie |
| Charlie Munger | 60C | 58C | LMAT |
| Terry Smith | 61C | 59C | LMAT |
Side-by-side metrics
| Metric | LMAT | XERS |
|---|---|---|
| Market cap | $2.32B | $1.13B |
| P/E (TTM) | 37.1x | 92.7x |
| EV/EBIT | 36.6x | 42.3x |
| ROIC (TTM) | 9.43% | 12.84% |
| Gross margin | 72.39% | 81.59% |
| Net margin | 24.35% | 3.81% |
| Revenue CAGR 5y | 12.75% | 55.75% |
| EPS CAGR 5y | 19.04% | - |
| Debt / Equity | 0.5x | 2.9x |
| Dividend yield | 0.84% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- Net margin24.35%vs 3.81%+84%
- Debt / Equity0.5xvs 2.9x+84%
- P/E (TTM)37.1xvs 92.7x+60%
XERS leads on
- Revenue CAGR 5y55.75%vs 12.75%+77%
- ROIC (TTM)12.84%vs 9.43%+27%
- Gross margin81.59%vs 72.39%+11%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.